Use of a singular ProGlide closure device after transfemoral transcatheter aortic valve replacement (TAVR) proved noninferior to the current standard practice of using two ProGlide devices, in the Chinese SINGLE-CLOSURE trial. The results were presented Tuesday in a late-breaking session at Transcatheter Cardiovascular Therapeutics (TCT) 2026 in San Diego, California, by Dr Jian'an Wang, MD, PhD, from the Second Affiliated Hospital Zhejiang University School of Medicine, in China. They were simultaneously published in the Journal of the American College of Cardiology (JACC). The Perclose ProGlide (Abbott Vascular) is a widely used suture-mediated vascular closure device (VCD), used in over 20 million vascular closures globally. After TAVR, the standard protocol has been to deploy two ProGlide devices, often in an ‘X’ stitch formation to ensure a seal. However, Dr Wang stressed that major vascular complications continue to seriously impair the prognosis of TAVR patients. Single ProGlide use has been emerging in recent times, with evidence from registry and comparator studies suggesting it is feasible and safe. The SINGLE-CLOSURE trial was therefore launched in 844 patients (422 per protocol) testing noninferiority of single device use in the composite endpoint of major or minor access-site related vascular complication during index hospitalization. At baseline, both groups were of similar age (75 years in single vs 74 years in double ProGlide), gender-weighting (53.9% vs 55.7% male, respectively), mean body mass index (24.2 kg/m2 vs 23.7 kg/m2, respectively) and carried similar risk (median Society of Thoracic Surgeons score of 2.9% vs 2.7%). Computed tomography (CT) characteristics were also largely similar between the two groups, including the aortic annulus perimeter-derived diameter (a mean of 24.6 mm in the single group vs 24.4 mm in double), as were procedural characteristics, save for the number of closure devices used (462 in the single group vs 863 in double). The primary in-hospital major or minor access-site or access-related vascular complications endpoint occurred for 13.1% (57/436) of the single ProGlide group vs 15.1% (65/430) of those receiving two devices (absolute difference [AD]: -0.022; 95% confidence interval [CI]: -0.070 to 0.026; P for noninferiority = 0.013). Secondary vascular endpoints — including major vascular outcomes (occurring in 0.5% given single closure vs 1.4% given double), minor vascular complications (12.6% vs 13.7%, respectively) and access-related bleeding (7.3% vs 8.8%) — were predominantly minor, Dr Wang said. There was more frequent use of bailout device in the single closure group (2.5% vs 0.9%; risk ratio [RR]: 2.85; 1.44 to 4.87), however, unplanned vascular interventions were more frequent for the double group (4.1% vs 5.6%). Time to hemostasis was a mean 9.3 minutes in the single group bs 8.7 minutes in double. “Single-ProGlide was noninferior, with potential to simplify closure and reduce routine device use,” Dr Wang concluded in his slides. Potential benefit in lower BMI patients Dr Wang went on to present data from an exploratory analysis suggesting a potential benefit for patients with lower body mass index (BMI). The primary endpoint occurred for 24/209 (11.5%) of the subjects given a single ProGlide whose BMI was below 24 kg/m2 vs 37/231 (16%) given a double device (risk difference [RD]: -4.7; 95% CI: -9.1 to -0.2) whereas it occurred for 33/227 (14.5%) of those with a BMI of 24kg/m2 or higher given a single device vs 28/199 (14/1%) with a higher BMI (RD 0.5: 95% CI: -4.1 to 5.1; P for interaction = 0.008). Exploratory analysis also suggested a benefit in those with moderate-to-severe access-vessel calcification (P for interaction <0.001). Source:Liu X, Guo Y, Song G, et al. Single vs Double ProGlide Devices for Access Site losure after Transfemoral Aortic Valve Replacement. J Am Coll Cardiol 2026; DOI: 10.1016/j.jacc.2026.10.055. Image Caption: Jian'an Wang, MD, PhD, presents during a press conference Tuesday, November 3, at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference in San Diego. Image Credit: Screenshot by Nathan Gray, CRTonline.org.